Market News AIOpen the app

Apimeds Pharmaceuticals stock is going up today because its partner is working on a new blockchain project.

DealRead the original at Benzinga
Good for APUS

Apimeds' subsidiary signed a two-year deal with paid development work, adding a business opportunity. Work depends on milestones and testing, future operating fees are unset, and token benefits depend on launch.

APUS · Apimeds Pharmaceuticals US Inc.

AI read · Good for APUS

The AI's read

The signed contract gives MindWave paid development work and a chance to grow its blockchain services business. The work must meet milestones and pass BlockAssure's testing. Future operating fees are not set, and the token allocation depends on the token launching. MindWave also has a signed services deal with AQUAE, which includes fees. The companies only expect to pursue a longer deal later, so that part is not settled. The signed work supports a positive read, but the size of the fees and how much work gets completed remain uncertain.

Get alerts for APUS

Follow Apimeds Pharmaceuticals US Inc. (APUS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for APUS
Free on the App Store and Google Play, or on the web.